A Phase 2 interventional study of brentuximab vedotin and doxorubicin in Hodgkin Lymphoma, sponsored by Seagen Inc.. Terminated at 76 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing nivolumab in Hodgkin Disease — 17 open to participants now, 32 under way, 4 of them phase 3. Nivolumab · Hodgkin Disease.
Among the 52 studies testing nivolumab in Hodgkin Disease, this one is the 6th largest by enrollment, is one of 5 that started in 2019, is one of 33 in phase 2, and was the 25th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →17 of the 52 studies testing nivolumab in Hodgkin Disease are open now, in 11 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 2–21
National Research Center for Hematology, Russia · Sites in Russia
Ages 18–60
National Medical Research Radiological Centre of the Ministry of Health of Russia · Sites in Russia
Ages 18+
University of Washington · Sites in United States
Ages 18+
St. Petersburg State Pavlov Medical University · Sites in Russia
Ages 18–60
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 45 · Phase 3 5
First in 2012; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 52 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 52 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
22 studies in Hodgkin Disease by Pfizer: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 22 studies in Hodgkin Disease by Pfizer, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 2, and was the 18th registered.
Pfizer’s Hodgkin Disease studies by the year they started, since 2000.
8 of the studies testing nivolumab in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03681561Veronika BachanovaNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | 2026-11 |
| NCT03033914Memorial Sloan Kettering Cancer CenterA(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | 2027-01 |
| NCT02940301Ohio State University Comprehensive Cancer CenterIbrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | 2027-02-15 |
| NCT05162976City of Hope Medical CenterCC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | 2027-04-27 |
| NCT05272384National Cancer Institute (NCI)Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | 2027-06-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 52 studies testing nivolumab in Hodgkin Disease, from their registry updates:
Among Pfizer’s 22 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C).
The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses).
Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening.
Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.
This study will have three parts.
Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy, and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL) receiving granulocyte colony stimulating factor primary prophylaxis (G-PP) administration during treatment with frontline A+AVD. In Part A, participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Participants will be treated using institutional standard of care practices for the majority of treatment decisions.
Part B is designed to evaluate the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) as frontline treatment in participants with advanced cHL. In Part B, participants will be given AN+AD combination for 6 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage II with bulky mediastinal disease and Stage III or IV cHL.
Part C is designed to evaluate AN+AD as frontline treatment in participants with early stage cHL. In Part C, participants will be given AN+AD combination for 4 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage I or II cHL with non-bulky mediastinal disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treatment-naïve, classic Hodgkin lymphoma (cHL) participants
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
Drug: brentuximab vedotin · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine · Drug: G-CSF
Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
Drug: brentuximab vedotin · Drug: doxorubicin · Drug: dacarbazine · Drug: nivolumab
Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
Drug: brentuximab vedotin · Drug: doxorubicin · Drug: dacarbazine · Drug: nivolumab
1.2 mg/kg by IV infusion
Also known as: Adcetris, SGN-35
25 mg/m\^2 by IV infusion
6 mg/m\^2 by IV infusion
375 mg/m\^2 by IV infusion
Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
Also known as: filgrastim, pegfilgrastim
240 mg by IV infusion
Also known as: Opdivo
Febrile Neutropenia (FN) Rate (Part A)
The FN rate is defined as the number of participants who experience treatment-emergent FN.
Time frame: 7.5 months
Complete Response (CR) Rate at EOT (Parts B and C)
CR rate at EOT is defined as the percentage of participants with CR at EOT, according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Cheson 2016), in participants with previously untreated cHL.
Time frame: 7.8 months
Number of Participants With Adverse Events of Clinical Interest (AECI) (Part A)
An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with the treatment. Participants with peripheral neuropathy (PN) adverse events were summarized under AECI.
Time frame: Approximately up to 7.5 months
Primary Refractory Disease Rate (Part A)
The primary refractory disease rate is defined as the percentage of participants with less than complete response or relapse within 3 months of EOT, according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas
Time frame: 10.2 months
Complete Response Rate (Part A)
The complete response rate is defined as the percentage of participants with CR at EOT according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).
Time frame: 7.2 months
Physician-reported Progression Free Survival (PFS) (Part A)
The physician-reported PFS rate at 2 years is estimated based on Kaplan-Meier methodology. The determination of antitumor activity will be based on response assessments made according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).
Time frame: 24 months
Number of Participants With Subsequent Anticancer Therapy Utilization (Part A)
Number of participants with subsequent anticancer therapy have been reported in this outcome measure.
Time frame: 33.8 months
Actual Dose Intensity: Brentuximab Vedotin (Part A)
Time frame: 6.5 months
Actual Dose Intensity: Doxorubicin, Vinblastine, Dacarbazine (Part A)
Time frame: 6.5 months
Relative Dose Intensity (Part A)
Time frame: 6.5 months
Rate of Dose Reduction and Delays: Brentuximab Vedotin (Part A)
Time frame: 6.5 months
Rate of Dose Reduction and Delays: Doxorubicin (Part A)
Time frame: 6.5 months
Rate of Dose Reduction and Delays: Vinblastine (Part A)
Time frame: 6.5 months
Rate of Dose Reduction and Delays: Dacarbazine (Part A)
Time frame: 6.5 months
Incidence of Adverse Events (Parts B and C)
Time frame: 8.9 months
Incidence of Laboratory Abnormalities (Parts B and C)
Laboratory values were graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). As per NCI CTCAE version 4.03 grading, Grade 1 indicated mild or asymptomatic laboratory abnormalities, Grade 2 indicated moderate laboratory abnormalities, and Grade 3 indicated severe and 4 indicated life-threatening laboratory abnormalities.
Time frame: 8.9 months
Overall Response Rate (ORR) at EOT (Parts B and C)
ORR is defined as the percentage of participants with CR or partial response (PR) at EOT according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) in participants with previously untreated cHL.
Time frame: Up to 7.8 months
Duration of Response (DOR) at End of Study (Parts B and C)
DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. Duration of response was only calculated for the subgroup of participants achieving a CR or PR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.
Time frame: Up to 51.1 months
Duration of Complete Response (DOCR) (Parts B and C)
DOCR was defined as the time from start of the first documentation of CR to the first documentation of tumor progression (per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. DOCR was calculated for the subgroup of participants achieving CR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.
Time frame: Up to 51.1 months
Event Free Survival (EFS) Rate (Parts B and C)
EFS was defined as the time from the start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever occurred first. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. EFS rate was percentage of participants with EFS.
Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
PFS Rate (Parts B and C)
PFS was defined as the time from start of study treatment to first documentation of objective tumor progression or death. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.
Time frame: At months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42 from the start of study treatment
Overall Survival (OS) Rate (Parts B and C)
OS was defined as the time from start of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Kaplan-Meier method was used.
Time frame: At months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42 from the start of study treatment
| Milestone | Part A | Part B | Part C |
|---|---|---|---|
| Started | 41 | 58 | 156 |
| Treated | 40 | 57 | 154 |
| Completed | 31 | 0 | 1 |
| Not completed | 10 | 58 | 155 |
| Withdrew: Withdrawal by subject | 2 | 2 | 3 |
| Withdrew: Study termination by sponsor | 0 | 45 | 139 |
| Withdrew: Lost to follow-up | 4 | 10 | 10 |
| Withdrew: Death | 2 | 1 | 1 |
| Withdrew: Other | 2 | 0 | 2 |
The FN rate is defined as the number of participants who experience treatment-emergent FN.
| Participants | Part A |
|---|---|
| Any treatment-emergent FN | 5 |
| Treatment-related treatment-emergent FN | 5 |
| Grade 3 or higher treatment-emergent FN | 5 |
| Grade 3 or higher treatment-related treatment-emergent FN | 5 |
CR rate at EOT is defined as the percentage of participants with CR at EOT, according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Cheson 2016), in participants with previously untreated cHL.
| Percentage of participants | Part B | Part C |
|---|---|---|
| Complete Response (CR) Rate at EOT (Parts B and C) | 88 (76.3 to 94.9) | 92 (86.0 to 95.4) |
An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with the treatment. Participants with peripheral neuropathy (PN) adverse events were summarized under AECI.
| Participants | Part A |
|---|---|
| Number of Participants With Adverse Events of Clinical Interest (AECI) (Part A) | 32 |
The primary refractory disease rate is defined as the percentage of participants with less than complete response or relapse within 3 months of EOT, according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas
| percentage of participants | Part A |
|---|---|
| Primary Refractory Disease Rate (Part A) | 10 (2.8 to 23.7) |
The complete response rate is defined as the percentage of participants with CR at EOT according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).
| percentage of participants | Part A |
|---|---|
| Complete Response Rate (Part A) | 80 (64.4 to 90.9) |
The physician-reported PFS rate at 2 years is estimated based on Kaplan-Meier methodology. The determination of antitumor activity will be based on response assessments made according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).
| percentage of participants | Part A |
|---|---|
| Physician-reported Progression Free Survival (PFS) (Part A) | 89.23 (73.76 to 95.82) |
Number of participants with subsequent anticancer therapy have been reported in this outcome measure.
| Participants | Part A |
|---|---|
| Participants with any subsequent therapy | 6 |
| Consolidative radiotherapy: Radiotherapy | 3 |
| Consolidative radiotherapy: Proton radiation | 1 |
| Immunotherapy: Nivolumab | 1 |
| Maintenance: Nivolumab | 1 |
| Maintenance radiotherapy: Radiation therapy | 1 |
| Systemic therapy for progressive disease: Bendamustine monotherapy | 1 |
| Systemic therapy for relapsed disease: Nivolumab | 1 |
| mg/kg/week | Part A |
|---|---|
| Actual Dose Intensity: Brentuximab Vedotin (Part A) | 0.5 ± 0.1 |
| mg/m2/week | Part A |
|---|---|
| Doxorubicin | 11.8 ± 1.0 |
| Vinblastine | 2.7 ± 0.4 |
| Dacarbazine | 176.3 ± 15.2 |
| percentage of intended dose | Part A |
|---|---|
| Brentuximab vedotin | 91.0 ± 10.8 |
| Doxorubicin | 94.2 ± 8.2 |
| Vinblastine | 89.0 ± 13.6 |
| Dacarbazine | 94.0 ± 8.1 |
| Participants | Part A |
|---|---|
| Participants with any dose modification | 29 |
| Participants with any dose delay | 22 |
| Participants with any dose delay due to AE | 15 |
| Participants with any dose delay due to other reason | 14 |
| Participants with any dose reduction due to AE | 14 |
| Participants | Part A |
|---|---|
| Participants with any dose modification | 25 |
| Participants with any dose delay | 23 |
| Participants with any dose delay due to AE | 15 |
| Participants with any dose delay due to other reason | 15 |
| Participants with any dose reduction due to AE | 7 |
| Participants | Part A |
|---|---|
| Participants with any dose modification | 27 |
| Participants with any dose delay | 22 |
| Participants with any dose delay due to AE | 15 |
| Participants with any dose delay due to other reason | 14 |
| Participants with any dose reduction due to AE | 12 |
| Participants | Part A |
|---|---|
| Participants with any dose modification | 25 |
| Participants with any dose delay | 22 |
| Participants with any dose delay due to AE | 15 |
| Participants with any dose delay due to other reason | 14 |
| Participants with any dose reduction due to AE | 6 |
| Participants | Part B | Part C |
|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 57 | 153 |
| Treatment-related TEAE | 56 | 149 |
| Grade 3 or higher TEAE | 29 | 67 |
| Grade 3 or higher treatment-related TEAE | 19 | 52 |
| Any treatment-emergent serious adverse event (SAE) | 15 | 29 |
| Treatment-related treatment-emergent SAE | 8 | 19 |
| Participants who discontinued treatment due to TEAE | 4 | 4 |
| Participants who discontinued treatment due to treatment-related TEAE | 4 | 4 |
| TEAE leading to death | 0 | 0 |
Laboratory values were graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). As per NCI CTCAE version 4.03 grading, Grade 1 indicated mild or asymptomatic laboratory abnormalities, Grade 2 indicated moderate laboratory abnormalities, and Grade 3 indicated severe and 4 indicated life-threatening laboratory abnormalities.
| Participants | Part B | Part C |
|---|---|---|
| Hemoglobin high, Grade 1 | 0 | 4 |
| Hemoglobin high, Grade 2 | 0 | 0 |
| Hemoglobin high, Grade 3 | 0 | 0 |
| Hemoglobin high, Grade 4 | 0 | 0 |
| Hemoglobin low, Grade 1 | 37 | 96 |
| Hemoglobin low, Grade 2 | 10 | 6 |
| Hemoglobin low, Grade 3 | 1 | 1 |
| Hemoglobin low, Grade 4 | 0 | 0 |
| Leukocytes high, Grade 1 | 0 | 0 |
| Leukocytes high, Grade 2 | 0 | 0 |
| Leukocytes high, Grade 3 | 0 | 0 |
| Leukocytes high, Grade 4 | 0 | 0 |
| Leukocytes low, Grade 1 | 19 | 41 |
| Leukocytes low, Grade 2 | 12 | 24 |
| Leukocytes low, Grade 3 | 0 | 2 |
| Leukocytes low, Grade 4 | 0 | 0 |
| Lymphocytes high, Grade 1 | 0 | 0 |
| Lymphocytes high, Grade 2 | 1 | 3 |
| Lymphocytes high, Grade 3 | 0 | 0 |
| Lymphocytes high, Grade 4 | 0 | 0 |
| Lymphocytes low, Grade 1 | 11 | 31 |
| Lymphocytes low, Grade 2 | 17 | 22 |
| Lymphocytes low, Grade 3 | 7 | 9 |
| Lymphocytes low, Grade 4 | 1 | 0 |
| Neutrophils low, Grade 1 | 4 | 12 |
| Neutrophils low, Grade 2 | 14 | 38 |
| Neutrophils low, Grade 3 | 4 | 11 |
| Neutrophils low, Grade 4 | 2 | 3 |
| Platelets low, Grade 1 | 6 | 22 |
| Platelets low, Grade 2 | 1 | 1 |
| Platelets low, Grade 3 | 0 | 0 |
| Platelets low, Grade 4 | 0 | 0 |
| Alanine aminotransferase high, Grade 1 | 26 | 71 |
| Alanine aminotransferase high, Grade 2 | 3 | 16 |
| Alanine aminotransferase high, Grade 3 | 4 | 10 |
| Alanine aminotransferase high, Grade 4 | 0 | 0 |
| Albumin low, Grade 1 | 11 | 22 |
| Albumin low, Grade 2 | 3 | 6 |
| Albumin low, Grade 3 | 0 | 0 |
| Albumin low, Grade 4 | 0 | 0 |
| Alkaline phosphatase high, Grade 1 | 30 | 51 |
| Alkaline phosphatase high, Grade 2 | 2 | 1 |
| Alkaline phosphatase high, Grade 3 | 0 | 0 |
| Alkaline phosphatase high, Grade 4 | 0 | 0 |
| Amylase high, Grade 1 | 3 | 15 |
| Amylase high, Grade 2 | 2 | 6 |
| Amylase high, Grade 3 | 0 | 6 |
| Amylase high, Grade 4 | 0 | 0 |
| Aspartate aminotransferase high, Grade 1 | 27 | 75 |
| Aspartate aminotransferase high, Grade 2 | 1 | 7 |
| Aspartate aminotransferase high, Grade 3 | 2 | 1 |
| Aspartate aminotransferase high, Grade 4 | 0 | 0 |
| Calcium corrected for albumin high, Grade 1 | 12 | 18 |
| Calcium corrected for albumin high, Grade 2 | 0 | 0 |
| Calcium corrected for albumin high, Grade 3 | 0 | 0 |
| Calcium corrected for albumin high, Grade 4 | 0 | 0 |
| Calcium corrected for albumin low, Grade 1 | 7 | 5 |
| Calcium corrected for albumin low, Grade 2 | 0 | 1 |
| Calcium corrected for albumin low, Grade 3 | 0 | 0 |
| Calcium corrected for albumin low, Grade 4 | 0 | 0 |
| Ionized calcium high, Grade 1 | 0 | 0 |
| Ionized calcium high, Grade 2 | 0 | 0 |
| Ionized calcium high, Grade 3 | 0 | 0 |
| Ionized calcium high, Grade 4 | 0 | 0 |
| Ionized calcium low, Grade 1 | 0 | 0 |
| Ionized calcium low, Grade 2 | 0 | 0 |
| Ionized calcium low, Grade 3 | 0 | 0 |
| Ionized calcium low, Grade 4 | 0 | 0 |
| Creatinine high, Grade 1 | 47 | 127 |
| Creatinine high, Grade 2 | 5 | 11 |
| Creatinine high, Grade 3 | 1 | 0 |
| Creatinine high, Grade 4 | 0 | 0 |
| Estimated glomerular filtration rate low, Grade 1 | 1 | 8 |
| Estimated glomerular filtration rate low, Grade 2 | 4 | 10 |
| Estimated glomerular filtration rate low, Grade 3 | 0 | 0 |
| Estimated glomerular filtration rate low, Grade 4 | 0 | 0 |
| Glucose high, Grade 1 | 45 | 69 |
| Glucose high, Grade 2 | 5 | 9 |
| Glucose high, Grade 3 | 1 | 13 |
| Glucose high, Grade 4 | 1 | 0 |
| Glucose low, Grade 1 | 12 | 18 |
| Glucose low, Grade 2 | 1 | 0 |
| Glucose low, Grade 3 | 0 | 0 |
| Glucose low, Grade 4 | 0 | 0 |
| Lipase high, Grade 1 | 9 | 13 |
| Lipase high, Grade 2 | 1 | 6 |
| Lipase high, Grade 3 | 5 | 6 |
| Lipase high, Grade 4 | 0 | 3 |
| Phosphate low, Grade 1 | 1 | 3 |
| Phosphate low, Grade 2 | 7 | 9 |
| Phosphate low, Grade 3 | 2 | 4 |
| Phosphate low, Grade 4 | 0 | 0 |
| Potassium high, Grade 1 | 3 | 7 |
| Potassium high, Grade 2 | 0 | 1 |
| Potassium high, Grade 3 | 0 | 0 |
| Potassium high, Grade 4 | 0 | 0 |
| Potassium low, Grade 1 | 9 | 19 |
| Potassium low, Grade 2 | 0 | 0 |
| Potassium low, Grade 3 | 2 | 0 |
| Potassium low, Grade 4 | 1 | 0 |
| Sodium high, Grade 1 | 2 | 3 |
| Sodium high, Grade 2 | 0 | 0 |
| Sodium high, Grade 3 | 0 | 1 |
| Sodium high, Grade 4 | 0 | 0 |
| Sodium low, Grade 1 | 11 | 25 |
| Sodium low, Grade 2 | 0 | 0 |
| Sodium low, Grade 3 | 2 | 2 |
| Sodium low, Grade 4 | 0 | 0 |
| Total bilirubin high, Grade 1 | 1 | 8 |
| Total bilirubin high, Grade 2 | 2 | 0 |
| Total bilirubin high, Grade 3 | 0 | 0 |
| Total bilirubin high, Grade 4 | 0 | 0 |
| Urate high, Grade 1 | 0 | 0 |
| Urate high, Grade 2 | 0 | 0 |
| Urate high, Grade 3 | 10 | 28 |
| Urate high, Grade 4 | 0 | 1 |
ORR is defined as the percentage of participants with CR or partial response (PR) at EOT according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) in participants with previously untreated cHL.
| Percentage of participants | Part B | Part C |
|---|---|---|
| Overall Response Rate (ORR) at EOT (Parts B and C) | 93 (83.0 to 98.1) | 96 (91.7 to 98.6) |
DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. Duration of response was only calculated for the subgroup of participants achieving a CR or PR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.
| Months | Part B | Part C |
|---|---|---|
| Duration of Response (DOR) at End of Study (Parts B and C) | NA (NA to NA) | NA (NA to NA) |
DOCR was defined as the time from start of the first documentation of CR to the first documentation of tumor progression (per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. DOCR was calculated for the subgroup of participants achieving CR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.
| Months | Part B | Part C |
|---|---|---|
| Duration of Complete Response (DOCR) (Parts B and C) | NA (NA to NA) | NA (NA to NA) |
EFS was defined as the time from the start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever occurred first. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. EFS rate was percentage of participants with EFS.
| Percentage of participants | Part B | Part C |
|---|---|---|
| Month 3 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 6 | 98.25 (88.19 to 99.75) | 98.66 (94.74 to 99.66) |
| Month 9 | 94.67 (84.39 to 98.25) | 98.66 (94.74 to 99.66) |
| Month 12 | 92.89 (82.15 to 97.27) | 98.66 (94.74 to 99.66) |
| Month 15 | 91.03 (79.77 to 96.17) | 97.95 (93.79 to 99.34) |
| Month 18 | 91.03 (79.77 to 96.17) | 96.46 (91.70 to 98.51) |
| Month 21 | 86.89 (74.38 to 93.55) | 96.46 (91.70 to 98.51) |
| Month 24 | 86.89 (74.38 to 93.55) | 95.62 (90.49 to 98.02) |
| Month 27 | 86.89 (74.38 to 93.55) | 94.72 (89.19 to 97.46) |
| Month 30 | 86.89 (74.38 to 93.55) | 94.72 (89.19 to 97.46) |
| Month 33 | 84.54 (71.29 to 92.01) | 94.72 (89.19 to 97.46) |
| Month 36 | 84.54 (71.29 to 92.01) | 94.72 (89.19 to 97.46) |
| Month 39 | 84.54 (71.29 to 92.01) | 94.72 (89.19 to 97.46) |
| Month 42 | 84.54 (71.29 to 92.01) | — |
PFS was defined as the time from start of study treatment to first documentation of objective tumor progression or death. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.
| Percentage of participants | Part B | Part C |
|---|---|---|
| Month 3 | 100 (100 to 100) | 100 (100 to 100) |
| Month 6 | 100 (100 to 100) | 100 (100 to 100) |
| Month 9 | 96.36 (86.23 to 99.08) | 100 (100 to 100) |
| Month 12 | 94.55 (84.04 to 98.21) | 100 (100 to 100) |
| Month 15 | 92.65 (81.59 to 97.18) | 99.29 (95.04 to 99.90) |
| Month 18 | 92.65 (81.59 to 97.18) | 97.77 (93.26 to 99.28) |
| Month 21 | 88.44 (76.00 to 94.65) | 97.77 (93.26 to 99.28) |
| Month 24 | 88.44 (76.00 to 94.65) | 96.92 (91.99 to 98.84) |
| Month 27 | 88.44 (76.00 to 94.65) | 96.01 (90.64 to 98.33) |
| Month 30 | 88.44 (76.00 to 94.65) | 96.01 (90.64 to 98.33) |
| Month 33 | 86.05 (72.80 to 93.14) | 96.01 (90.64 to 98.33) |
| Month 36 | 86.05 (72.80 to 93.14) | 96.01 (90.64 to 98.33) |
| Month 39 | 86.05 (72.80 to 93.14) | 96.01 (90.64 to 98.33) |
| Month 42 | 86.05 (72.80 to 93.14) | — |
OS was defined as the time from start of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Kaplan-Meier method was used.
| Percentage of participants | Part B | Part C |
|---|---|---|
| Month 3 | 100 (100 to 100) | 100 (100 to 100) |
| Month 6 | 100 (100 to 100) | 100 (100 to 100) |
| Month 9 | 100 (100 to 100) | 100 (100 to 100) |
| Month 12 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 15 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 18 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 21 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 24 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 27 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 30 | 98.25 (88.19 to 99.75) | 100 (100 to 100) |
| Month 33 | 98.25 (88.19 to 99.75) | 98.73 (91.35 to 99.82) |
| Month 36 | 98.25 (88.19 to 99.75) | 98.73 (91.35 to 99.82) |
| Month 39 | 98.25 (88.19 to 99.75) | 98.73 (91.35 to 99.82) |
| Month 42 | 98.25 (88.19 to 99.75) | 98.73 (91.35 to 99.82) |
Collected over All-Cause Mortality: Up to 54.5 Months, Serious Adverse Events, and Non-Serious Adverse Events were followed for up to 8.9 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A | 2/40 (5%) | 19/40 (47.5%) | 40/40 (100%) |
| Part B | 1/57 (1.8%) | 15/57 (26.3%) | 57/57 (100%) |
| Part C | 1/154 (0.6%) | 29/154 (18.8%) | 153/154 (99.4%) |
| Event | Part A | Part B | Part C |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 5/40 | 0/57 | 0/154 |
| PneumoniaInfections and infestations | 4/40 | 0/57 | 2/154 |
| PyrexiaGeneral disorders | 3/40 | 3/57 | 6/154 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/40 | 3/57 | 2/154 |
| Abdominal painGastrointestinal disorders | 2/40 | 0/57 | 0/154 |
| PainGeneral disorders | 2/40 | 0/57 | 0/154 |
| HypotensionVascular disorders | 2/40 | 0/57 | 0/154 |
| COVID-19 pneumoniaInfections and infestations | 0/40 | 2/57 | 0/154 |
| SepsisInfections and infestations | 0/40 | 2/57 | 1/154 |
| AnaemiaBlood and lymphatic system disorders | 1/40 | 0/57 | 0/154 |
| Event | Part A | Part B | Part C |
|---|---|---|---|
| NauseaGastrointestinal disorders | 28/40 | 40/57 | 105/154 |
| Peripheral sensory neuropathyNervous system disorders | 25/40 | 26/57 | 72/154 |
| FatigueGeneral disorders | 15/40 | 29/57 | 74/154 |
| DiarrhoeaGastrointestinal disorders | 13/40 | 26/57 | 38/154 |
| ConstipationGastrointestinal disorders | 18/40 | 22/57 | 69/154 |
| AlopeciaSkin and subcutaneous tissue disorders | 12/40 | 21/57 | 34/154 |
| HeadacheNervous system disorders | 13/40 | 15/57 | 36/154 |
| Bone painMusculoskeletal and connective tissue disorders | 12/40 | 10/57 | 10/154 |
| VomitingGastrointestinal disorders | 9/40 | 16/57 | 25/154 |
| Decreased appetiteMetabolism and nutrition disorders | 11/40 | 9/57 | 22/154 |
| Age, Continuous(years) | Part A | Part B | Part C | Total |
|---|---|---|---|---|
| Median | 28 (18 to 71) | 35 (19 to 78) | 31 (18 to 77) | 31 (18 to 78) |
| Sex: Female, Male(Participants) | Part A | Part B | Part C | Total |
|---|---|---|---|---|
| Female | 16 | 27 | 86 | 129 |
| Male | 25 | 31 | 70 | 126 |
| Ethnicity (NIH/OMB)(Participants) | Part A | Part B | Part C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 10 | 22 | 36 |
| Not Hispanic or Latino | 34 | 46 | 127 | 207 |
| Unknown or Not Reported | 3 | 2 | 7 | 12 |
| Race (NIH/OMB)(Participants) | Part A | Part B | Part C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 1 | 6 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 2 | 1 | 9 |
| White | 31 | 50 | 131 | 212 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 3 | 4 | 17 | 24 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Part A | Part B | Part C | Total |
|---|---|---|---|---|
| Grade 0 | 27 | 34 | 124 | 185 |
| Grade 1 | 13 | 23 | 28 | 64 |
| Grade 2 | 0 | 0 | 2 | 2 |
| Missing | 1 | 1 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Nov 2022, 45 months.
Results were first posted in Dec 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab